William A. Magioncalda

A selection of Mr. Magioncalda’s recent representations include:

Initial Public Offerings and Follow-on Offerings

• The underwriters in Royalty Pharma plc’s $2.5 billion initial public offering and $728 million secondary follow-on offering
• Moderna, Inc. in its $1.34 billion and $500 million public follow-on offerings
• The underwriters in Exscientia’s $350.4 million initial public offering and concurrent $160 million private placements
• The underwriters in Sarepta Therapeutics’ $575 million public follow-on offering
• The underwriters in Krystal Biotech’s $200 million and $125 million public follow-on offerings
• The underwriters in Omega Therapeutic’s $144.6 million initial public offering
• The underwriters in Ambrx Biopharma’s $126 million initial public offering
• The underwriters in Valneva SE’s $107.6 million initial public offering and $102 million public follow-on offering
• Codiak BioSciences in its $82.5 million initial public offering and $66.4 million public follow-on offering
• HOOKIPA Pharma, Inc. in its $84 million initial public offering
• The underwriters in Repare Therapeutics, Inc.’s $253 million initial public offering and $101.2 million public follow-on offering
• The underwriters in Harmony Biosciences’ $147.6 million initial public offering
• The underwriters in Pandion Therapeutics’ $135 million initial public offering
• Goldman Sachs & Co. and other underwriters in Arvinas, Inc.’s $120 million initial public offering and $150 million and $400 million public follow-on offerings
• The underwriters in Immunomedics, Inc.’s $420 million and $285 million public follow-on offerings

Other Corporate Transactions

• GameChange Solar in its $150 million preferred stock financing 
• The initial purchasers in Royalty Pharma’s $6 billion and $1.3 billion offerings of its convertible senior notes
• Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
• The initial purchasers in Dynavax Technologies’ $200 million offering of its convertible senior notes
• Galecto in its $50 million “at-the-market” offering
• Cowen as sales agent in multiple ATM facilities, including for Albireo Pharma, Ovid Therapeutics, Syndax Pharmaceuticals and Dynavax Technologies
• Akili Interactive Labs, Inc. in its $55 million Series C financing
• Even Financial, Inc. in its $25 million Series B financing and $18 million Series A financing
• Aircall.io, Inc. in its $29 million Series B financing